Which antianginal drug is contraindicated in patients taking phosphodiesterase-5 inhibitors and why?

Explanation

## Nitrates + PDE-5 Inhibitors: A Dangerous Combination **Key Point:** Nitrates are **absolutely contraindicated** in patients taking phosphodiesterase-5 (PDE-5) inhibitors (sildenafil, tadalafil, vardenafil) due to the risk of **life-threatening hypotension**. ### Mechanism of the Interaction ```mermaid flowchart LR A["Nitrate (e.g., GTN)"]:::action --> B["↑ NO in vascular smooth muscle"]:::outcome C["PDE-5 inhibitor (e.g., sildenafil)"]:::action --> D["↓ cGMP breakdown"]:::outcome B --> E["↑ cGMP levels"]:::outcome D --> E E --> F["Severe vasodilation"]:::urgent F --> G["Profound hypotension"]:::urgent G --> H["Syncope, MI, stroke"]:::urgent ``` **High-Yield:** Both drug classes work on the **nitric oxide–cGMP pathway**: - **Nitrates** → increase NO production - **PDE-5 inhibitors** → prevent cGMP degradation - **Combined effect** → synergistic, uncontrolled vasodilation ### Clinical Consequences 1. **Severe hypotension** — can drop >30 mmHg systolic 2. **Reflex tachycardia** — worsens myocardial ischemia 3. **Syncope, stroke, MI** — especially in elderly or volume-depleted patients 4. **Prolonged effect** — tadalafil has a 36-hour half-life; interaction risk persists **Warning:** This is a **high-yield exam trap**. Students often confuse this with other drug interactions. The key is recognizing that **both classes target the same pathway**. ### Safe Alternatives for Angina in PDE-5 Inhibitor Users | Drug Class | Safe? | Reason | |---|---|---| | **Nitrates** | ❌ No | Synergistic hypotension | | **Beta-blockers** | ✓ Yes | Different mechanism (sympathetic blockade) | | **Calcium channel blockers** | ✓ Yes | Different mechanism (L-type channel blockade) | | **Ivabradine** | ✓ Yes | Different mechanism (I_f inhibition) | **Clinical Pearl:** If a patient with erectile dysfunction requires antianginal therapy, use beta-blockers or calcium channel blockers. If nitrates are *essential* (e.g., acute MI), PDE-5 inhibitors must be withheld for ≥24 hours (or ≥48 hours for tadalafil).